Welcome to our dedicated page for Adia Nutrition SEC filings (Ticker: ADIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings related to Adia Nutrition Inc. (OTCQB: ADIA). While no individual filings are listed in the supplied data, the company has publicly announced that it submitted a Form 10 registration statement to the SEC. According to Adia Nutrition, this filing is a key step toward becoming a fully reporting company under the Securities Exchange Act of 1934.
Once effective, a Form 10 registration typically leads to regular disclosures such as annual reports (Form 10‑K), quarterly reports (Form 10‑Q), and current reports (Form 8‑K). For a business like Adia Nutrition, which focuses on regenerative medicine, stem cell therapies, and clinic operations, these filings can provide detail on revenue sources such as service fees, product sales, equity stakes, and insurance-billed healthcare treatments, as described in the company’s public statements.
On Stock Titan, Adia Nutrition’s SEC filings page is designed to surface these documents as they become available from the SEC’s EDGAR system. AI-powered summaries help explain the key points of lengthy filings, highlight important risk factors and business descriptions, and clarify financial disclosures for investors who may not wish to read full documents. When Forms 3, 4, or 5 are filed, this page can also be used to review insider transaction reports, offering additional context on executive and director share activity.
As Adia Nutrition advances its regulatory reporting, this page will serve as a centralized location to review its registration statement, periodic reports, and other SEC documents, with AI tools available to make complex regulatory language easier to understand.
Adia Nutrition, Inc. files a Form 10 to register its Common A Stock under the Exchange Act and describe its transition from a dormant shell into an operating regenerative medicine and supplements business. After court-appointed custodianship and several control changes, the company now runs Adia Med clinics and Adia Labs, focusing on autologous stem cell procedures and umbilical cord stem cell biologics such as AdiaVita and AdiaLink, alongside an 18% stake in supplement seller Cement Factory.
Revenue grew to $637,145 for the nine months ended September 30, 2025, mainly from biologic product sales and medical procedures, but the company still recorded a net loss and has an accumulated deficit over $15 million, leading auditors to raise substantial doubt about its ability to continue as a going concern. Operations depend heavily on a related-party credit line, a third‑party lab, and navigating complex FDA and AATB rules for human tissue products. The filing also highlights significant regulatory, competitive, liquidity and penny‑stock risks, as well as concentrated voting control through a single preferred share class.
FAQ
What is the current stock price of Adia Nutrition (ADIA)?
What is the market cap of Adia Nutrition (ADIA)?
